Invest New Drugs. 2015 Oct;33(5):1048-57. doi: 10.1007/s10637-015-0262-2. Epub 2015 Jun 17.

First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics  of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.

Kim KP, Park SJ, Kim JE, Hong YS, Lee JL, Bae KS, Cha H, Kwon SK, Ro S, Cho J, Kim TW.

Abstract

PURPOSE: The aim of the present study was to assess the safety, maximum tolerated dose(MTD), pharmacokinetics, pharmacodynamics, and efficacy of single and multiple doses of intravenous CG200745, a novel histone deacetylase (HDAC) inhibitor, in patients with advanced solid malignancies.

EXPERIMENTAL DESIGN:

Two to six patients received intravenous CG200745 according to the 2 + 4 dose-escalating method. This first-in-human trial was comprised of two parts: Part 1 was a single ascending dose, and Part 2 was multiple ascending doses weekly for 3 weeks, and then 1 week off. For the first cycle, pharmacokinetic sampling for CG200745 and pharmacodynamic sampling for acetylated histone H4 in peripheral blood mononuclear cells (PBMCs) were performed on day 1 for Part 1 and on days 1 and 15 for Part 2. Examination of acetylated histone H4 in pre- and post-biopsy samples was performed in accessible patients.

RESULTS:

In all, 28 patients were treated at 13 dose levels (1.8-250 mg/m(2)) and received a total of 71 cycles of CG200745. Hematologic toxicities included grade 3/4 neutropenia (22.2 %) that did not last a week and non-hematologic toxicities included fatigue (22.2 %) and anorexia (16.7 %) that did not exceed grade 2. No dose-limiting toxic effects were noted. Dose proportionality was observed for both the maximum concentration and area under the curve. The elimination half-life was 5.67 ± 2.69 h (mean ± standard deviation). An increase in PBMC acetylated histone H4 was observed at dose levels up to 51 mg/m(2), which plateaued at higher dose levels. At 24 h, 75 % of patients(6/8) showed higher relative acetylation in tumor tissue compared to PBMCs. Although there was no partial or complete response, 57.1 % of patients (16/28) had stable disease that lasted at least 6 weeks.

CONCLUSIONS:

CG200745 can be safely administered at effective dose levels that inhibit HDAC in PBMCs and tumor tissue. Although MTD was not reached, further escalation was not performed because acetylated histone H4 plateaued at dose levels higher than 51 mg/m(2). Additional phase II trials are recommended at 250 mg/m(2).

KEYWORDS:

CG200745; First-in-human dose; HDAC inhibitor; Pharmacodynamics; Pharmacokinetics

PMID:

26076682

DOI:

10.1007/s10637-015-0262-2